
Jurczak on BTK Inhibitors and the Future of B-Cell Lymphoma Therapy
Wojciech Jurczak, MD, PhD, head of the department of oncology at Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland, discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase (BTK) …